Gilead Sciences Announces Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Gilead Sciences (GILD) raises Revenue Guidance Following 3Q Beat; Maxim Group Reiterates Buy
October 28, 2015 1:47 PM EDTMaxim Group reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD), and raised the price target to $137.00 (from $129.00), following the company's 3Q earnings results. Gilead delivered a very strong quarter well ahead of street estimates. Gilead raised guidance for full year... More
Gilead Sciences (GILD) PT Raised at Cowen as HCV Sales Drive Beat
October 28, 2015 8:53 AM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and bumped his price target on Gilead Sciences (NASDAQ: GILD) to $130.00 (from $125.00) as HCV sales drove the top and bottom-line and guidance was ralsed.
Nadeau commented, "Gilead reported solid Q3 financials with HCV revenue... More
Gilead Sciences (GILD) Tops Q3 EPS by 33c, Updates FY15 Guidance
October 27, 2015 4:02 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $3.22, $0.33 better than the analyst estimate of $2.89. Revenue for the quarter came in at $8.3 billion versus the consensus estimate of $7.82 billion.
Product Sales
Total product sales for the third quarter of 2015 were $8.2 billion compared to $6.0... More
